Audentes Therapeutics has announced its plans to build a new gene therapy manufacturing facility at an investment of US$109 million in Sanford, North Carolina, US.
The new facility will cover an area of approximately 135,000ft² and will be engaged in biopharmaceutical manufacturing of genetic medicines by using Adeno-Associated Virus (AAV) vector approach.
It will serve as a flagship production plant and support the company’s strategy of developing and bringing genetic drugs rapidly to patients.
The proposed manufacturing facility will also increase the company’s growth plans for expanding the geographic and therapeutic scope and creating a global supply chain.
The initial phase of the investment is planned to take over 18 months of time, while the remaining investment will be made in two additional planned expansion phases.
The facility is expected to be operational in 2021.
Key partners in the project are North Carolina Department of Commerce, North Carolina Biotechnology Centre, North Carolina General Assembly, Economic Partnership of North Carolina, Sanford City, Lee County, Sanford Area Growth Alliance, and the North Carolina Community College System.